Amikacin Disulfate Cas 39831-55-5

Specification

Welcome to contact with us to get more information.

Amikacin Disulfate is a salt form of the antibiotic amikacin, specifically where the amikacin base is combined with two sulfate groups. It is a semi-synthetic aminoglycoside antibiotic derived from kanamycin A.

Primary Uses:

Amikacin disulfate is a potent, broad-spectrum antibiotic used almost exclusively in hospital settings for serious, often life-threatening infections, particularly those caused by Gram-negative bacteria. Its major uses include:

1. Treatment of Resistant Infections: It is a key drug for infections resistant to other aminoglycosides (like gentamicin or tobramycin) and other antibiotics, due to its stability against many bacterial-inactivating enzymes.

2. Gram-Negative Bacilli Infections: Used for severe infections caused by bacteria such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella, and Acinetobacter. Common infection sites include:

• Complex urinary tract infections

  Bloodstream infections (sepsis)

  Pneumonia (especially hospital-acquired/ventilator-associated)

  Post-surgical or intra-abdominal infections

3. Mycobacterial Infections: It is a second-line drug in the treatment of multidrug-resistant tuberculosis (MDR-TB).

4. Combination Therapy: Often used in combination with a beta-lactam antibiotic (like a penicillin or cephalosporin) for synergistic effect and to broaden coverage, especially in febrile neutropenia or empirical treatment of severe sepsis.

Key Administration & Safety Notes:

• Route: Administered only by intravenous (IV) infusion or intramuscular (IM) injection.

  Critical Monitoring: Requires careful therapeutic drug monitoring (measuring peak and trough blood levels) due to its narrow therapeutic index.

  Major Toxicities: The two main dose-limiting side effects are:

1. Nephrotoxicity (kidney damage)

2. Ototoxicity (irreversible damage to the inner ear, leading to hearing loss and/or balance disturbances).

In summary, amikacin disulfate is a powerful, last-line injectable antibiotic reserved for severe, resistant bacterial infections in controlled hospital settings, where its benefits are weighed against significant potential toxicity.

Packages

Delivery

Payment term

* Wire Transfer/Telegraphic Transfer

* Western Union

* MoneyGram

* L/C

Contact information

Spring Zhang

Email: export@fortunachem.com  

Skype: Fortunachem201304       

Wechat/Whatsapp: 18007136271

Tel:   +86-27-59207892

Website: www.fortunachem.com